Skip to main content

Table 3 Clinical characteristics of respective training and test study populations

From: Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease

Training set n = 158 Age (years) Median (95% CI) Gender Male: Female CA19-9 (KU/L) Median (95% CI) Bilirubin (μmol/L) Median (95% CI)
PDAC (n = 84) 66 (64.0-69.0) 47:37 137.5 (62.0-161.4) 31 (24.5-54.3)
CP (n = 32) 53 (48.0-58.6) 20:12 24.5 (11.0-41.0) 7 (6.0-10.0)
BBO (n = 13) 72 (60.7-77.4) 11:2 89 (13.5-228.3) 69 (11.0-108.6)
HC (n = 29) 44 (29.9-54.0) 14:15 4 (2.0-6.0) NA
Test Set n = 83 Age (years) Median (95% CI) Gender Male: Female CA19-9 (KU/L) Median (95% CI) Bilirubin (μmol/L) Median (95% CI)
PDAC (n = 43) 68 (64.2-71.8) 24:19 116 (54.9-164.4) 51 (19.6-114.0)
CP (n = 17) 53 (45.1-62.0) 10:7 12 (8.0-24.9) 6 (5.0-10.0)
BBO (n = 7) 64 (38.4-78.5) 3:4 37 (4.5-181.3) 100 (44.9-374.9)
HC (n = 16) 56.5 (36.7-62.1) 9:7 3 (2.6-8.4) NA
  1. PDAC = Cancer, CP = Chronic Pancreatitis, BBO = Benign Biliary Obstruction, HC = Healthy Controls.